Diabetes and Immunity - Pharmacist Digest

STAT+: In small study, weight loss drug boosts immune cells that help fight cancer

STAT

MAY 10, 2023

Prior research has shown that people with obesity have deficiencies in their “natural killer” cells, or NK cells — immune cells that help in combating cancer.

Immunity

STAT+: Pharmalittle: New medication appears to stave off type 1 diabetes; CRISPR pioneer founds another startup

STAT

FEBRUARY 16, 2023

Here’s the latest, and do keep in touch … A new medication appears to be helping stave off the development of type 1 diabetes , Nature writes. Approved last November in the United States, it’s also the first drug proven to delay the onset of an autoimmune disorder.

Diabetes

STAT+: Brigham creates institute focused on immunology with record $100 million gift

STAT

MAY 10, 2023

The institute will be led by Brigham immunologist and principal investigator Vijay Kuchroo, who will lead teams dedicated to studying chronic inflammation and discovering drugs for conditions associated with it, such as food allergies and type 1 diabetes. Continue to STAT+ to read the full story…

Immunity

Immunity Immunization Hospitals Diabetes

STAT+: Flagship Pioneering launches Quotient, a new biotech, in two countries

STAT

NOVEMBER 21, 2023

Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes. Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age.

Diabetes

Sanofi to acquire Provention Bio, adding to portfolio TZIELD for type diabetes (T1D)

LifeProNow

MARCH 13, 2023

-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9

Diabetes

Vertex pays CRISPR to use its gene editing tech for diabetes drugs

BioPharma Dive

MARCH 27, 2023

Vertex will license CRISPR technology to develop insulin-producing islet cells that are more resistant to immune rejection, adding to other efforts directed at Type 1 diabetes.

Diabetes

Gene-edited cell replacement therapy for diabetes set to enter the clinic

Outsourcing Pharma

NOVEMBER 16, 2021

have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). CRISPR Therapeutics and ViaCyte, Inc.

Diabetes

FDA approves first drug to delay type 1 diabetes

European Pharmaceutical Review

NOVEMBER 18, 2022

Tzield (teplizumab-mzwv), the first drug to help prolong the onset of stage 3 type 1 diabetes in adults and children over eight years old with stage 2 type 1 diabetes, has been approved by the US Food and Drug Administration (FDA). The drug binds to certain immune system cells and delays progression to stage 3 type 1 diabetes.

Diabetes

STAT+: Pharmalittle: We’re reading about obesity drugs and suicidal thoughts, a FDA official’s conflicts, and more

STAT

AUGUST 21, 2024

… A new observational study found that people taking Ozempic and Wegovy appeared to experience suicidal thoughts at a higher rate than people on other drugs, though experts raised concerns about the methodology and the findings contradict what some other studies have found about the class of GLP-1 diabetes and obesity drugs , STAT writes.

Diabetes

Common drug could facilitate “huge step-change” in managing type 1 diabetes

European Pharmaceutical Review

DECEMBER 7, 2023

Results from a world-first human trial, published in the New England Journal of Medicine , has shown that a drug called baricitinib has promise as the first disease-modifying treatment of its kind for type 1 diabetes, that can be administered as a tablet. 

Diabetes

FDA fast tracks type 1 diabetes cell therapy from Vertex

pharmaphorum

MARCH 11, 2021

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy for diabetes. . The aim is to replace the pancreatic tissue that is damaged by the autoimmune reaction that underlies type 1 diabetes.

Diabetes

Lonza and Vertex to partner to manufacture diabetes cell therapies

European Pharmaceutical Review

JUNE 27, 2023

Lonza and Vertex Pharmaceuticals Incorporated have agreed to collaborate to support the manufacture of Vertex’s Type 1 diabetes cell therapy portfolio. It is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection.

Diabetes

Parvus and Resilience expand partnership to develop IBD drug candidate

Pharmaceutical Business Review

JANUARY 9, 2025

It works by restoring organ-specific immune tolerance without conceding systemic immunity. These cells then migrate to the site of tissue inflammation, where they work to restore immune tolerance. These assets can activate in vivo generation of antigen-specific Treg cells thereby stopping and curing autoimmune disease.

Immunity

Chikungunya vaccine approved for select groups by CDC advisory panel

STAT

FEBRUARY 28, 2024

vaccination policy when Mandy Cohen, director of the Centers for Disease Control and Prevention, signs off on the recommendation from the Advisory Group on Immunization Practices. Babies infected around the time of birth, adults 65 and older and people with heart disease, diabetes or high blood pressure are at higher risk of severe disease.

Vaccines

STAT+: Pharmalittle: We’re reading about an Amgen drug for lung cancer, a Novo plant fire, and more

STAT

MAY 17, 2024

It’s an overreaction of the immune system. Novo Nordisk is “optimistic” that a fire at a construction site in Kalundborg, Denmark, a key manufacturing hub, will not delay its plans to boost production capacity of its popular weight loss drug Wegovy and Ozempic for diabetes , Reuters reports.

Diabetes

How immune cells "sniff out" pathogens

World Pharma News

NOVEMBER 12, 2024

Immune cells are capable of detecting infections just like a sniffer dog, using special sensors known as Toll-like receptors, or TLRs for short. The approach that they took might help to speed up the search for drugs to combat infectious diseases, cancer, diabetes or dementia.

Immunity

Immunity Immunization Diabetes Hospitals

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

Pharmaceutical Technology

JANUARY 10, 2023

On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.

Diabetes

Diabetes Immunity Immunization Communication

A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked.

NY Times

NOVEMBER 27, 2021

A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.

Diabetes

Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition

pharmaphorum

AUGUST 17, 2020

Phase 3 development in the bleeding disease thrombocytopenia is expected to begin by the end of the year as long as COVID-19 does not impact on trials and there is also an ongoing phase 2 development programme in various other immune diseases.

Immunity

Vertex buys diabetes cell therapy rival ViaCyte for $320m

pharmaphorum

JULY 11, 2022

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The post Vertex buys diabetes cell therapy rival ViaCyte for $320m appeared first on.

Diabetes

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. The post Provention finally gets FDA nod for type 1 diabetes drug teplizumab appeared first on.

Diabetes

Study finds air pollution lowers Covid vaccine response

Express Pharma

APRIL 7, 2023

The findings, published in the journal Environmental Health Perspectives , provide further evidence on the adverse effects of air pollution on the immune system. However, the role of long-term exposure to air pollution on hybrid immunity (infection plus vaccination) deserves further investigation, they added.

Vaccines

Vaccines Immunity Immunization Diabetes

Novo Nordisk crowns cell therapy pipeline with $598m Heartseed deal

pharmaphorum

JUNE 1, 2021

Novo Nordisk – which is already active in stem cell therapies with a candidate in early development for type 1 diabetes – is on the hook for up to $598 million in total licensing and milestone payments plus royalties on sales if HS-001 reaches the market.

Immunity

mRNA licensing agreements rise 800% in value as confidence grows beyond vaccines

Express Pharma

OCTOBER 16, 2024

Ophelia Chan, Business Fundamentals Senior Analyst at GlobalData, comments, “The COVID-19 pandemic highlighted the key advantages of mRNA technology in vaccine development, including rapid production, precise immune targeting, and streamlined manufacturing- factors that drove the success of mRNA-based COVID-19 vaccines.”

Vaccines

Vaccines Immunity Immunization Diabetes

AI tool may help doctors select best drugs for COVID patients

pharmaphorum

NOVEMBER 12, 2021

It also takes into account existing and chronic health factors such as diabetes, obesity, and conditions that affect the immune system can play a big role in risk factors related to COVID-19.

Diabetes

Integrated Nanotherapeutics gains funds for new T1D treatment

Pharmaceutical Technology

SEPTEMBER 10, 2024

Integrated Nanotherapeutics secured funds to propel the development of an immune tolerizing therapeutic for Type 1 diabetes.

Diabetes

Why Balancing Blood Sugar is Vital for Hashimoto’s Health

The Thyroid Pharmacist

SEPTEMBER 2, 2022

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

Diabetes

Diabetes Health and Personal Care Stores Immunization Immunity

Alzheimer’s Research UK starts AI-based drug hunt with Exscientia

pharmaphorum

FEBRUARY 16, 2021

In 2019, Novartis also bought into the category via a $310 million takeover of IFM Therapeutics, which is developing NLRP3 drugs for atherosclerosis and non-alcoholic steatohepatitis (NASH), while UK startup NodThera raised $55 million last year for its own NLRP3 programme, eyeing NASH and diabetes.

Diabetes

BioMed X and Sanofi partner to leverage AI for drug development

Pharmaceutical Technology

OCTOBER 25, 2022

As proof-of-concept (PoC), chronic immune-mediated diseases such as atopic dermatitis (AD) and inflammatory bowel disease (IBD) will be the focus areas of the preliminary model. For the project, deep datasets and capabilities of Sanofi will be leveraged to potentially transform the practice of medicine using digital data and AI.

Drug Development

Drug Development Diabetes Immunity Immunization

GSK launches shingles vaccine, Shingrix in India

Express Pharma

APRIL 24, 2023

Adults above 50 years of age and those suffering from chronic conditions such as diabetes, heart disease and kidney diseases are at an increased risk of developing shingles because of weakened immunity. Vaccination is the only effective preventive option.”

Vaccines

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Diabetes

Diabetes Labelling Immunity Immunization

Developing a new treatment paradigm for IgAN

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Diabetes

Diabetes Labelling Immunity Immunization

Latest WHO Covid-19 vaccine guidance may decrease future demand

Pharmaceutical Technology

APRIL 3, 2023

The latest guidance applies to the current phase of the pandemic and reflects the impact of the Omicron variant, which has led to high levels of immunity in all age groups through both vaccination efforts and infections across the globe.

Vaccines

Getting Involved as a Pre-Pharmacy Student

Pharmacy Is Right For Me

SEPTEMBER 24, 2024

Annually, SNPhA serves over 100,000 patients and community members through eight key initiatives that we focus our service on: Bridging the Gap (Networking and Professional Engagement) Fighting Diabetes Legislative, Membership Benefits, and Immigration Mental Health Operation Immunization Power to End Stroke Project Keepsake (Chronic (..)

Diabetes

First gene therapy approved for Haemophilia A

European Pharmaceutical Review

JUNE 30, 2023

Most patients given Roctavian received corticosteroids to suppress the immune system for the gene therapy to be effective and safe. Following the infusion, the mean annualised bleeding rate decreased from 5.4 bleeds per year at baseline to 2.6 bleeds per year. The FDA granted approval of Roctavian to BioMarin Pharmaceutical Inc.

Diabetes

Is Stevia Good or Bad for Hashimoto’s Disease?

The Thyroid Pharmacist

OCTOBER 7, 2022

I knew he was right — sugar can contribute to a yeast overgrowth, lowered immunity, blood sugar issues, weight gain, diabetes, and a whole host of health problems (1-3) — but I was a sugar addict, and it was devastating to think that I would have to let go of this old friend and not have any sweetness in my life.

Diabetes

Diabetes Immunity Immunization Labelling

Understanding the microbiome as an ‘overlooked critical organ’

pharmaphorum

APRIL 26, 2022

As more research has been conducted, closer and unexpected links have been found between the microbiome of the gut, as one example, and other areas of the body, such as brain health and the immune system. Compelling advantages.

Immunity

Immunity Immunization Diabetes Drug Development

Avesthagen and Apollo AyurVAID partner to develop medical foods and dietary supplements

Express Pharma

AUGUST 28, 2024

The key areas of focus will include managing chronic diseases such as diabetes, cardiovascular conditions, metabolic disorders, onco-nutrition, immunity, cognitive health, and mental well-being. Avesthagen’s subsidiaries, Avesta Nordic Research and Avesta Good Earth Foods, will be responsible for manufacturing the products.

Hospitals

Hospitals Diabetes Immunity Immunization

Roche’s fast-growing eye drug Vabysmo set for EU approval

pharmaphorum

JULY 25, 2022

Vabysmo (faricimab) has been recommended by the EMA’s human medicines committee as a treatment for neovascular or wet age-related macular degeneration (AMD) and diabetic macular oedema (DME), so could be fully approved and ready to roll out in the next few months, subject to pricing and reimbursement negotiations.

Diabetes

Novo Nordisk and Aspect join forces for bioprinting tissue therapeutics

Pharmaceutical Technology

APRIL 12, 2023

The Canadian biotech Aspect Biosystems has announced a partnership with Novo Nordisk to produce bioprinted tissue therapeutics for diabetes. On April 12, the Dutch pharmaceutical giant Novo Nordisk announced a partnership to grow its diabetes portfolio. The company is developing therapeutic platforms for the liver and the pancreas.

Diabetes

Diabetes Immunity Immunization Communication

What is Stiff-Person Syndrome?

Board Vitals - Pharmacist

DECEMBER 9, 2022

Patients with SPS often have another autoimmune disease, including type 1 diabetes, pernicious anemia, thyroiditis, vitiligo, and certain types of cancers. Intravenous immune globulin (IVIG) C. Most people who live with SPS start experiencing symptoms between the ages of 30 and 60. Is there a cure for Stiff-Person Syndrome?

Immunity

HepaStem seems most promising pipeline agent for decompensated cirrhosis due to NASH: GlobalData

Express Pharma

SEPTEMBER 12, 2023

tumor formation, immune reactions, and therapy failure). tumor formation, immune reactions, and therapy failure). As such, it is unsurprising that a stem cell therapy is being considered for the treatment of DC due to NASH.

Diabetes

US FDA approves GSK’s Arexvy, world’s first RSV vaccine for older adults

Express Pharma

MAY 3, 2023

Older adults, including those with underlying medical conditions such as diabetes and chronic heart and lung disease, are at increased risk of severe RSV illness and drive the majority of RSV hospitalisations. RSV is a common, contagious virus that can lead to potentially serious respiratory illness.

Vaccines